DDInter1821 DDInter1676
Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Tizanidine {u} (Compound) resembles {v} (Compound) Brimonidine
Tizanidine {u} (Compound) binds {v} (Gene) CYP1A2
Tizanidine {u} (Compound) upregulates {v} (Gene) CDK6
Tizanidine {u} (Compound) palliates {v} (Disease) multiple sclerosis
Tizanidine {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic alpha2-Agonists
Tizanidine {u} (Compound) downregulates {v} (Gene) USP22
Tizanidine {u} (Compound) causes {v} (Side Effect) Autonomic nervous system imbalance
Tizanidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Tizanidine (Compound) resembles Brimonidine (Compound)
Tizanidine (Compound) binds CYP1A2 (Gene)
Tizanidine (Compound) upregulates CDK6 (Gene)
Tizanidine (Compound) palliates multiple sclerosis (Disease)
Tizanidine (Compound) is included by Adrenergic alpha2-Agonists (Pharmacologic Class)
Tizanidine (Compound) downregulates USP22 (Gene)
Tizanidine (Compound) causes Autonomic nervous system imbalance (Side Effect)
Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a